Dbv Technologies SA (DBV.PA) stock: key figures, P/E, revenue and dividend

Health Care · France · ISIN FR0010417345

Price
2.38 EUR
Market cap
332.76 m EUR
P/E (2025)
–
P/S (2025)
59.04
Dividend yield
0.00 %
Net margin
-2,713.59 %
Return on equity (ROE)
-90.61 %
Return on assets (ROA)
-65.43 %

Dbv Technologies SA financials

Fiscal year20242025
Revenue4.00 m USD5.64 m USD
Gross profit3.00 m USD-18.34 m USD
Operating income–-158.92 m USD
EBIT-116.00 m USD–
Net income-114.00 m USD-152.94 m USD
Diluted EPS – continuing operations-1.18 USD–

Full history since 2010, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Dbv Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.